In today’s recent session, 0.79 million shares of the Standard BioTools Inc (NASDAQ:LAB) have been traded, and its beta is 1.68. Most recently the company’s share price was $1.73, and it changed around -$0.07 or -3.78% from the last close, which brings the market valuation of the company to $640.66M. LAB at last check was trading at a discount to its 52-week high of $3.16, offering almost -82.66% off that amount. The share price’s 52-week low was $1.57, which indicates that the recent value has risen by an impressive 9.25% since then. We note from Standard BioTools Inc’s average daily trading volume that its 3-month average coming to 2.63 million.
Standard BioTools Inc (NASDAQ:LAB) trade information
Instantly LAB has been showing red trend so far today with a performance of -3.78% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently down -21.63% year-to-date, but still down -17.92% over the last five days. On the other hand, Standard BioTools Inc (NASDAQ:LAB) is -33.64% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $3.25, which translates to bulls needing to increase their stock price by 46.77% from its current value. Analyst projections state that LAB is forecast to be at a low of $3.25 and a high of $3.25.
Standard BioTools Inc (LAB) estimates and forecasts
Standard BioTools Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -11.64 percent over the past six months and at a 43.90% annual growth rate that is well above the industry average of 17.70%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 8.72%.
LAB Dividends
Standard BioTools Inc’s next quarterly earnings report is expected to be released in July.
